Malignant Pleural Mesothelioma
📧 Sign up to get email alerts when something new happens for Malignant Pleural Mesothelioma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-02-29FDA Approved: PEMETREXED — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for a generic pemetrexed disodium product from BluePoint Laboratories.
-
FDA approval · 2024-02-29FDA Approved: PEMETREXED — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for pemetrexed disodium (Pemetrexed) submitted by BluePoint Laboratories.
-
CLINICAL_TRIALS trial_result · 2024-02-20Clinical Trial Update: Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants [Phase 2]
Phase 2 window-of-opportunity trial of defactinib in surgically resectable malignant pleural mesothelioma was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2024-01-26Clinical Trial Update: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma [Phase 1, Phase 2]
A clinical trial update for RSO-021 in malignant pleural effusion due to advanced/metastatic solid tumors including mesothelioma across Phas…
-
FDA approval · 2023-12-11FDA Approved: PEMETREXED — Original Application (Solco Healthcare US, LLC)
FDA approved the original generic application for pemetrexed (PEMETREXED) by Solco Healthcare US, LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-09-25FDA Approved: PEMETREXED — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for pemetrexed disodium (pemetrexed) submitted by Fresenius Kabi USA, LLC.
-
FDA approval · 2023-08-29FDA Approved: PEMETREXED DISODIUM — Supplemental Application (Dr. Reddys Laboratories Inc)
FDA approved a supplemental application for pemetrexed disodium submitted by Dr. Reddy's Laboratories Inc.
-
FDA approval · 2023-08-29FDA Approved: PEMETREXED — Supplemental Application (Accord Healthcare Inc.)
The FDA has approved Accord Healthcare Inc.'s supplemental application for pemetrexed (PEMETREXED), related to the approved pemetrexed produ…
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma [Phase 2]
Phase II clinical trial update for PF-03446962 in advanced malignant pleural mesothelioma has completed.
-
FDA approval · 2023-07-12FDA Approved: PEMETREXED — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for pemetrexed submitted by BluePoint Laboratories. This action approves the generic pemetrexed …
-
FDA approval · 2023-06-14FDA Approved: IMJUDO — Supplemental Application (AstraZeneca Pharmaceuticals LP)
The FDA approved a supplemental application for IMJUDO (tremelimumab) from AstraZeneca.
-
CLINICAL_TRIALS trial_result · 2023-05-31Clinical Trial Update: Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas [Phase 1, Phase 2]
Phase 1/2 trial investigating oral decitabine with tetrahydrouridine as epigenetic priming to enhance pembrolizumab in inoperable/unresectab…
-
FDA approval · 2023-05-22FDA Approved: PEMRYDI RTU — Original Application (Amneal Pharmaceuticals LLC)
FDA approved PEMRYDI RTU (pemetrexed disodium) from Amneal Pharmaceuticals as an Original Application, providing a ready-to-use formulation …
-
FDA approval · 2023-04-21FDA Approved: PEMETREXED — Supplemental Application (Sandoz Inc.)
The FDA approved a supplemental application for pemetrexed disodium, enabling the generic pemetrexed product from Sandoz Inc. to be marketed…
-
FDA approval · 2023-02-27FDA Approved: PEMETREXED — Supplemental Application (Sagent Pharmaceuticals)
FDA approved a supplemental application for pemetrexed disodium from Sagent Pharmaceuticals, enabling continued availability of this generic…
-
CLINICAL_TRIALS trial_result · 2023-02-01Clinical Trial Update: Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma [Phase 2]
Phase 2 trial of transarterial chemoperfusion using cisplatin, methotrexate, and gemcitabine for unresectable pleural mesothelioma has compl…
-
FDA approval · 2022-12-14FDA Approved: PEMFEXY — Supplemental Application (Eagle Pharmaceuticals, Inc.)
FDA approved a supplemental application for PEMFEXY (pemetrexed) from Eagle Pharmaceuticals.
-
FDA approval · 2022-12-13FDA Approved: PEMETREXED — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved the original application for pemetrexed disodium from Meitheal Pharmaceuticals Inc., a generic version of the cancer drug pemet…
-
FDA approval · 2022-11-22FDA Approved: PEMETREXED — Supplemental Application (Teva Pharmaceuticals, Inc.)
FDA approved a supplemental application for pemetrexed filed by Teva Pharmaceuticals, Inc., expanding the drug's labeled uses.
-
CLINICAL_TRIALS trial_result · 2022-11-07Clinical Trial Update: Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM [Phase 2]
Phase 2 clinical trial evaluating pleurectomy/decortication with or without chemotherapy in early-stage malignant pleural mesothelioma.
-
CLINICAL_TRIALS trial_result · 2022-09-22Clinical Trial Update: An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma [Phase 2]
Phase 2 trial update evaluating amatuximab (MORAb-009) for malignant pleural mesothelioma has completed with results posted.
-
FDA approval · 2022-06-22FDA Approved: PEMETREXED — Original Application (Hospira, Inc.)
FDA approved Hospira, Inc.'s original application for pemetrexed (injectable), authorizing a generic pemetrexed product with the established…
-
CLINICAL_TRIALS trial_result · 2022-06-16Clinical Trial Update: MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma [Phase 2]
Phase 2 clinical trial update evaluating MTG201 plus nivolumab for relapsed malignant pleural mesothelioma.
-
FDA approval · 2022-05-25FDA Approved: PEMETREXED — Original Application (Zydus Lifesciences Limited)
The FDA approved a generic pemetrexed disodium product (PEMETREXED DISODIUM) from Zydus Lifesciences Limited.
-
FDA approval · 2022-05-25FDA Approved: PEMETREXED DISODIUM — Original Application (Dr. Reddys Laboratories Inc)
FDA approval of a generic pemetrexed disodium product (ANDA) submitted by Dr. Reddy's Laboratories Inc.